On February 23, 2024 Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, reported that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City (Press release, Ocuphire Pharma, FEB 23, 2024, View Source [SID1234640424]). Company management will also be participating in one-on-one meetings throughout the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BIO CEO & Investor Conference – February 26-27, 2024
Title: Ocuphire Pharma, Inc. (OCUP) Company Presentation
Presenter: George Magrath, M.D. M.B.A, M.S.
Date: Tuesday, February 27, 2024
Time: 2:45 – 3:00pm ET
Location: Plymouth Room, Marriott Marquis, New York, NY

If you are interested in arranging a 1×1 meeting, please contact your conference representative or send an email to [email protected]. For more details, please see the Investors and Events section of Ocuphire’s corporate website.